U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1PD-L1 Inhibitor – – New Indication Marks Second FDA Approval for Trodelvy in 2021 – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of Trodelvy ® for use in adult patients with locally advanced or metastatic …
Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1PD-L1 Inhibitor – – New Indication Marks Second FDA Approval for Trodelvy in 2021 –
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study – – Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis – Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted full approval to Trodelvy ® for adult patients with …
Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study – – Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis